13.73
Schlusskurs vom Vortag:
$13.79
Offen:
$13.81
24-Stunden-Volumen:
366.59K
Relative Volume:
0.54
Marktkapitalisierung:
$557.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.6764
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-3.65%
1M Leistung:
+1.78%
6M Leistung:
+20.54%
1J Leistung:
-71.73%
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
13.73 | 578.77M | 0 | -168.05M | -146.15M | -5.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
2024-12-16 | Bestätigt | Oppenheimer | Outperform |
2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
2024-11-05 | Eingeleitet | Jefferies | Buy |
2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-09-23 | Eingeleitet | Guggenheim | Buy |
2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
2024-02-21 | Eingeleitet | William Blair | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-07-31 | Eingeleitet | Wedbush | Outperform |
2023-07-26 | Eingeleitet | BofA Securities | Buy |
2023-02-14 | Eingeleitet | Cowen | Outperform |
2022-10-18 | Eingeleitet | Truist | Buy |
2022-07-26 | Eingeleitet | BTIG Research | Buy |
2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
2020-05-04 | Eingeleitet | Jefferies | Buy |
2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Is Keros Therapeutics Inc. a good long term investmentTremendous portfolio expansion - jammulinksnews.com
What drives Keros Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Keros Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - Autocar Professional
What analysts say about Keros Therapeutics Inc. stockMarket-crushing stock picks - Autocar Professional
(KROS) Trading Signals - news.stocktradersdaily.com
Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser
Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks
Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times
Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com
Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser
How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser
What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat
Trend Tracker for (KROS) - news.stocktradersdaily.com
Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener
ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com
KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):